DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in AI-based cardiovascular imaging, announces its participation in the American Heart Association (AHA) Scientific Sessions 2026, November 6 to 9 at McCormick Place Convention Center in Chicago, Illinois. Cleerly will share primary results from PARAMOUNT, the first randomized trial to compare personalized care guided by AI-based quantitative coronary CT analysis (AI-QCT) with usual care in symptomatic patients with suspected coronary artery disease (CA
See full post here as originally published on this site
